Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic
Back A, Freeman-Young T, Morgan L, Sethi T, Baker K, Myers S, McGregor B, Harvey K, Tai M, Kollefrath A, Thomas B, Sorta D, Kaelen M, Kelmendi B, Gooley T. Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic. JAMA Network Open 2024, 7: e2449026. PMID: 39636638, PMCID: PMC11621983, DOI: 10.1001/jamanetworkopen.2024.49026.Peer-Reviewed Original ResearchConceptsAdvanced practice practitionersSymptoms of depressionMontgomery-Asberg Depression Rating ScalePosttraumatic stress disorderSymptoms of burnoutMontgomery-Asberg Depression Rating Scale scoreSymptoms of posttraumatic stress disorderFrontline carePsilocybin therapyRandomized clinical trialsSevere symptoms of depressionMental health diagnosesScore changesImprove symptoms of depressionCOVID-19 pandemicPCL-5Intention-to-treat principleMedication sessionsDepression Rating ScalePCL-5 scoresPsychological morbidityHealth diagnosisMain OutcomesPractice practitionersUS clinicians